Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

We report long-term clinical outcomes and immune responses observed from a phase 1 trial of agonist CD40 monoclonal antibody (mAb) and blocking CTLA-4 mAb in patients with metastatic melanoma. Twenty-four patients previously untreated with checkpoint blockade were enrolled. The agonistic CD40 mAb CP...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncoimmunology
Main Authors: Bajor, David L., Mick, Rosemarie, Riese, Matthew J., Huang, Alex C., Sullivan, Brendan, Richman, Lee P., Torigian, Drew A., George, Sangeeth M., Stelekati, Erietta, Chen, Fang, Melenhorst, J. Joseph, Lacey, Simon F., Xu, Xiaowei, Wherry, E. John, Gangadhar, Tara C., Amaravadi, Ravi K., Schuchter, Lynn M., Vonderheide, Robert H.
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2018
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6169575/
https://ncbi.nlm.nih.gov/pubmed/30288340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1468956
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki